DelveInsight’s “Idiopathic Thrombocytopenic Purpura Market Insight, Epidemiology And Market Forecast – 2032” report offers an unparalleled, in-depth analysis of historic and forecasted idiopathic thrombocytopenic purpura epidemiology, current treatment algorithms, emerging drug candidates, and market dynamics across the United States, EU4 (Germany, France, Italy and Spain), the United Kingdom, and Japan.
Idiopathic Thrombocytopenic Purpura, also known as immune thrombocytopenia, is an autoimmune disorder where the body destroys its own platelets, leading to easy bruising and bleeding. It can be acute or chronic and affects both adults and children. Common symptoms include petechiae, nosebleeds, and prolonged bleeding. Treatment ranges from steroids and IVIG to newer targeted therapies.
According to DelveInsight’s evaluation, the immune thrombocytopenia therapeutics market was valued at approximately USD 3.16 billion in 2022 across the 7MM, and is expected to grow at a significant CAGR during the forecast period (2025-2032). The United States is the largest contributor, accounting for about two-thirds of the 7MM market.
Download the Immune Thrombocytopenia Market report to understand which factors are driving the market @ Immune Thrombocytopenia Market Trends.
The total idiopathic thrombocytopenic purpura prevalent cases in the 7MM were estimated at around 186K in 2024, reflecting a substantial patient pool and underlying unmet medical need. Geographically, the United States reported approximately 67K immune thrombocytopenia prevalent cases in 2024, with adults comprising 90% and children 10% of the diagnosed population.
Discover evolving trends in the Immune Thrombocytopenia patient pool forecasts @ Immune Thrombocytopenia Epidemiological Analysis.
The current standard of care for immune thrombocytopenia includes corticosteroids, intravenous immunoglobulins (IVIG), anti-D immunoglobulin, and thrombopoietin receptor agonists (TPO-RAs). TPO-RAs, such as romiplostim and eltrombopag, held the majority share of the idiopathic thrombocytopenic purpura therapeutics market in 2024, owing to their proven efficacy in elevating platelet counts and favorable long-term safety profiles. Second-line options, rituximab, splenectomy, and off-label immunosuppressants, remain essential for refractory and chronic cases, but concerns regarding infection risk and variability in response have driven the search for safer, targeted agents.
The immune thrombocytopenia therapeutic pipeline is rapidly advancing with novel agents targeting distinct disease pathways. Key highlights include rilzabrutinib, an oral BTK inhibitor from Sanofi now in phase 3 trials after showing durable responses. The FcRn antagonist efgartigimod (argenx) has also completed phase 3 studies, demonstrating significant platelet responses and reduced bleeding. Additionally, Sanofi’s complement inhibitor sutimlimab has shown a remarkably rapid onset of action in refractory immune thrombocytopenia. Other promising approaches include BAFF inhibitors like ianalumab (Novartis) and various plasma cell-targeting therapies. This diverse pipeline represents a major shift toward precision medicine, offering new hope for patients with refractory idiopathic thrombocytopenic purpura.
A significant development in the treatment landscape for immune thrombocytopenia is the ongoing FDA review of rilzabrutinib, an investigational oral Bruton tyrosine kinase (BTK) inhibitor. The drug has received fast track designation, with a regulatory decision expected by its PDUFA target date of August 29, 2025. Rilzabrutinib has also been granted orphan drug designation in the US, EU, and Japan for the treatment of ITP.
Discover recent advancements in the Immune Thrombocytopenia landscape @ Immune Thrombocytopenia Recent Developments.
Furthermore, the LUNA3 Phase 3 trial (NCT04562766) evaluated rilzabrutinib in adults with persistent or chronic ITP. The study met its primary endpoint, showing that a significantly higher proportion of patients treated with rilzabrutinib achieved stable platelet counts compared to those who received a placebo. The trial is expected to be completed by August 2026.
Competitive intensity in the immune thrombocytopenia market is rising, driven by strategic partnerships, licensing agreements, and acquisitions. Rigel Pharmaceuticals’ collaboration with Kissei Pharmaceuticals for rilzabrutinib and Principia Biopharma’s alliance with Sanofi for lanalumab, exemplify the robust co-development and co-commercialization strategies aiming to optimize global reach and reimbursement potential. Moreover, MorphoSys’s expansion into the immune thrombocytopenia space via BI-204 acquisition and UCB’s focus on FcRn blockade illustrate the sector’s maturing competitive landscape.
Looking ahead, the immune thrombocytopenia market is expected to undergo substantial transformation. This growth will be driven by several key factors, including improved epidemiological surveillance and advancements in diagnostic tools, which are expected to expand the diagnosed and treated patient population. The anticipated approval of innovative oral and subcutaneous therapies targeting B cells, Fc receptors, and complement pathways will further diversify treatment options and improve outcomes.
Additionally, there is a growing emphasis on personalized medicine, with biomarker-driven patient stratification playing a pivotal role in tailoring therapies to individual needs. Strategic partnerships and alliances are also expected to enhance global market reach and address regional disparities in treatment access. Ongoing investment in clinical research will continue to focus on developing therapies for refractory and relapsed ITP cases, ensuring that even the most treatment-resistant patients have access to effective care.
Table of Contents
1. Key Insights
2. Executive Summary of Idiopathic Thrombocytopenic Purpura
3. Competitive Intelligence Analysis for Idiopathic Thrombocytopenic Purpura
4. Idiopathic Thrombocytopenic Purpura: Market Overview at a Glance
5. Idiopathic Thrombocytopenic Purpura: Disease Background and Overview
6. Idiopathic Thrombocytopenic Purpura Patient Journey
7. Idiopathic Thrombocytopenic Purpura Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Idiopathic Thrombocytopenic Purpura Unmet Needs
10. Key Endpoints of Idiopathic Thrombocytopenic Purpura Treatment
11. Idiopathic Thrombocytopenic Purpura Marketed Products
12. Idiopathic Thrombocytopenic Purpura Emerging Therapies
13. Idiopathic Thrombocytopenic Purpura: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Idiopathic Thrombocytopenic Purpura
17. KOL Views
18. Idiopathic Thrombocytopenic Purpura Market Drivers
19. Idiopathic Thrombocytopenic Purpura Market Barriers
20. Appendix
Related Reports
Idiopathic Thrombocytopenic Purpura Pipeline Insight
Idiopathic Thrombocytopenic Purpura pipeline insight provides comprehensive insights about the Idiopathic Thrombocytopenic Purpura pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Idiopathic Thrombocytopenic Purpura companies, including Novartis, Takeda, Amgen, Rigel Pharmaceuticals, GENERIUM Pharmaceuticals, Principia Biopharma, UCB, CSL Behring, MorphoSys, and Biotest, among others.
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Arpit AnandEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services
